Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q4 FY24 results · Jan–Mar 2024
Ajanta Pharma reported revenue from operations of ₹1,054.08 crore (up 19.5% from Q4 FY23) and net profit of ₹202.72 crore (up 65.8% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,054.08 | 881.84 | +19.5% | 1,105.15 | −4.6% |
| Other income | 35.50 | 36.83 | −3.6% | 13.59 | +161.2% |
| Total income | 1,089.58 | 918.67 | +18.6% | 1,118.74 | −2.6% |
| Profit before tax | 278.04 | 152.05 | +82.9% | 290.91 | −4.4% |
| Net profit for the period | 202.72 | 122.25 | +65.8% | 210.03 | −3.5% |
| Attributable to shareholders of the company | 196.33 | — | — | — | — |
| EPS, basic (₹) | 16.10 | 9.54 | +68.8% | 16.68 | −3.5% |
| Net margin (%) | 19.2 | 13.9 | 19.0 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 926.07 | 848.86 | +9.1% | 1,085.29 | −14.7% |
| Other income | 33.68 | 36.75 | −8.4% | 13.73 | +145.3% |
| Total income | 959.75 | 885.61 | +8.4% | 1,099.02 | −12.7% |
| Profit before tax | 225.94 | 147.96 | +52.7% | 305.14 | −26.0% |
| Net profit for the period | 162.69 | 117.21 | +38.8% | 220.15 | −26.1% |
| EPS, basic (₹) | 12.92 | 9.15 | +41.2% | 17.48 | −26.1% |
| Net margin (%) | 17.6 | 13.8 | 20.3 |
Consolidated
- Filed with BSE
- 03 May 2024, 12:46 IST
- Board meeting
- 02 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 May 2024, 12:46 IST
- Board meeting
- 02 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE